Shares of Mylan (MYL) were higher Tuesday after a U.S. District Court rejected competitor Teva Pharmaceuticals' (TEVA) claims of patent infringement on a drug used to treat multiple sclerosis. This opens the door for Mylan which has been working on a more affordable, generic version of the drug. This comes as embattled EpiPen-maker said it was under investigation by the Federal Trade Commission for violation of antitrust laws. However, the company released a statement saying, "Mylan received an information request from the FTC months ago as part of a preliminary investigation. Any suggestion that Mylan took any inappropriate or unlawful actions to prevent generic competition is without merit."
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.